Top-News

Soligenix Aktie News

Aktie
WKN:  A40DDP ISIN:  US8342236044 US-Symbol:  SNGX Branche:  Biotechnologie Land:  USA
1,495 $
-0,135 $
-8,28%
1,2841 € 18:38:04 Uhr
Depot/Watchlist
Marktkapitalisierung *
5,06 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Soligenix News

14.04.25 - PR Newswire
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks PR Newswire
25.03.25 - PR Newswire
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants PR Newswire
21.03.25 - PR Newswire
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results PR Newswire
06.03.25 - PR Newswire
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March PR Newswire
04.02.25 - PR Newswire
Soligenix to Present at BIO CEO & Investor Conference
Soligenix to Present at BIO CEO & Investor Conference PR Newswire
16.01.25 - PR Newswire
Soligenix to Present at Upcoming Investor Conferences
Soligenix to Present at Upcoming Investor Conferences PR Newswire
14.01.25 - PR Newswire
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-​Stage Cutaneous T-Cell Lymphoma PR Newswire
16.12.24 - PR Newswire
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »